688687 Beijing Kawin Technology Share-Holding
- 30.19
- -0.09-0.30%
Beijing Kawin Technology Share-Holding News
Kain Technology (688687.SH) will distribute 2.5 yuan for every 10 shares in 2023. The stock registration date is May 21
Zhitong Finance App News, Kain Technology (688687.SH) announced that the company will implement the 2023 equity distribution and distribute a cash dividend of 2.5 yuan (tax included) for every 10 shares to all shareholders. The share registration date is May 21.
Kain Technology (688687) In-depth Report: Kailiwei, a new hepatitis C drug, is expected to create a second growth curve by selling probiotics derived from the new hepatitis B drug currently being developed by China and China
Hepatitis C: With the support of national policies, the diagnosis and treatment rate is expected to increase rapidly. Judging from the number of hepatitis C patients in China after expanding medical insurance indications, according to Polaris data, it is estimated that 9 people were infected with HCV in China in 2020
Kain Technology (688687.SH): Zhuoshangwan enquiry to transfer 2.34% of shares at a transfer price of 29.57 yuan/share
Kain Technology (688687.SH) announced that the price of the company's current inquiry and transfer is 29.57 yuan/share, and the number of shares transferred is 4 million shares. The actual number of transfers accounted for 2.34% of the total share capital. Zhuoshangwan participated in this inquiry transfer. Zhuoshangwan is a shareholding platform for the company's employees. It is a co-actor of the company's controlling shareholders and actual controllers, and some of the company's directors, supervisors and senior management indirectly hold shares in Kain Technology through the above employee shareholding platform.
Kain Technology (688687.SH): This inquiry was transferred to 29.57 yuan/share
Gelonghui, May 7, 丨 Kain Technology (688687.SH) announced that according to the inquiry and subscription situation on May 7, 2024, the initial price of Kain Technology's shareholder inquiry transfer (hereinafter referred to as “this inquiry transfer”) was 29.57 yuan/share, which is 93.52% of the closing price of 31.62 yuan/share on this inquiry transfer pricing date (that is, May 6, 2024). The shares to be transferred have been fully subscribed.
Express News | Science and Technology Innovation Board Review: The Science and Technology Innovation 50 Index closed down 1.01%, and aerospace concept stocks surged
Shareholder of Kain Technology (688687.SH), Beijing Zhuoshangwan plans to transfer 2.34% of the company's shares in an inquiry
Kain Technology (688687.SH) disclosed the shareholder inquiry transfer plan. The shareholder that intends to participate in this inquiry and transfer is North...
We Think Beijing Kawin Technology Share-Holding (SHSE:688687) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Kellyne Technology (688687): Kailliwei's sales revenue increased by more than 200% year-on-year, and probiotic hepatitis B indications are progressing in an orderly manner
Sales revenue of the core product Kailiwei increased by more than 200% year over year. In 2023, the company achieved revenue of 1,412 billion yuan (+21.7% YoY), net profit attributable to mother of 117 million yuan (YoY +39.7%), after deducting net income from non-return to mother
Kain Technology (688687.SH): As of April 10, 2024, the number of shareholders of the company was 8,462
Gelonghui, April 15 | Kain Technology (688687.SH) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 8,462.
Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still h
Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still has room for growth in the long term; 2) R&D of innovative drugs is progressing steadily, and long-term interferons are being implemented soon. (Mainichi Keizai Shimbun)
Kellyne Technology (688687): Kailiwei's rapid release drives rapid performance growth, long-acting interferon-derived probiotics completed phase III clinical trials
Incident Kain Technology Co., Ltd. released its 2023 annual report: achieved revenue of 1,412 billion yuan in 2023, an increase of 21.73% over the previous year; realized net profit of 117 million yuan, an increase of 39.71% over the previous year; deducted net income from non-return to mother
Kain Technology (688687): Contrary growth shows resilience and is optimistic that subsequent risks will be cleared
Short-term performance is under pressure. I am optimistic that subsequent risks will clear the company's revenue of 1,412 billion yuan (+21.73% yoy) in 23 years, which will return to the mother of 117 million yuan (+39.71% yoy); of these, 4Q23 achieved revenue of 4.1 billion yuan
Are Beijing Kawin Technology Share-Holding Co., Ltd.'s (SHSE:688687) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
With its stock down 16% over the past week, it is easy to disregard Beijing Kawin Technology Share-Holding (SHSE:688687). However, stock prices are usually driven by a company's financials over the
Kellyne Technology (688687): Kailiwei achieved strong growth and production of long-acting interferon is about to be reported
Incident: The company released its 2023 annual report and 2024 quarterly report. The company achieved operating income of 1.41 billion yuan in 2023, an increase of 21.7% over the previous year; achieved net profit of 120 million yuan to mother, an increase of 39.7% over the previous year; achieved
Kane Technology (688687) 2023 Annual Report 2024 Quarterly Report Comment: Kailiwei's sales have increased dramatically, and the subsequent product pipeline is sufficient
Focusing on the anti-virus field, the main business is steady. On April 9, 2024, the company released its 2023 annual report. During the reporting period, the company achieved operating income of 1,412 billion yuan, an increase of 21.73% over the previous year; net profit attributable to mothers1
Minsheng Securities released a research report on April 10 stating that it gave Kain Technology (688687.SH) a recommended rating. The main reasons for the rating include: 1) focusing on the anti-virus field, with a steady main business; 2) deepening marke
Minsheng Securities released a research report on April 10 stating that it gave Kain Technology (688687.SH) a recommended rating. The main reasons for the rating include: 1) focusing on the anti-virus field, with a steady main business; 2) deepening market strategies for key products and steadily implementing product restructuring; 3) steadily increasing investment in R&D and speeding up R&D in the research pipeline. (Mainichi Keizai Shimbun)
Dragon Tiger List | 5 agencies wildly sold Kane Technology for 131 million yuan. Fang Xinxia, quantitative players', and player Xinyi joined forces to take first place, Zongshen Dongdong
The top three daily net purchases in the Dragon Tiger list are Shenzhen China A, Zhongrun Resources, and Tengda Technology
Dragon Tiger List丨Kain Technology fell 18.9%, and the net sales of the five institutions were 131 million yuan
Glonghui, April 10 | Kain Technology (688687.SH) hit a standstill today and eventually closed down 18.9%, with a turnover of 433 million yuan and a turnover rate of 9.26%. According to data from the Dragon Tiger List, the seller's five seats were all occupied by the agency, with a total net sales of 131 million yuan. The listed seats bought 47.2852 million yuan throughout the day and sold 131 million yuan, for a total net sale of 83.4061 million yuan.
Kane Technology (688687) Annual Report Review Report: Kailiwei achieved ultra-rapid growth in 2023 and subsequent volume is expected to accelerate
The company released its 2023 annual report. The company achieved operating income of 1,412 billion yuan in 2023, an increase of 21.73% year on year; net profit to mother was 117 million yuan, up 39.71% year on year; non-net profit deducted from mother 1.
Innovative drug concepts declined at the beginning of the market, and Kain Technology fell by more than 17%
Innovative drug concepts declined at the beginning of the market. Kain Technology fell by more than 17%, while many stocks such as Shanghai Yizhong, Yakshi Technology, Kangchen Pharmaceutical, and Sailong Pharmaceutical fell.
Analysis
Price Target
No Data
